Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

v3.24.1.1.u2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
COSTS AND EXPENSES:    
Research and development $ 7,377,940 $ 6,654,094
General and administrative 4,623,546 2,051,207
Total costs and expenses 12,001,486 8,705,301
LOSS FROM OPERATIONS (12,001,486) (8,705,301)
OTHER (LOSS) INCOME:    
Loss on valuation of warrants (9,900,000)  
Interest income, net 319,849 124,034
Total other (loss) income, net (9,580,151) 124,034
NET LOSS $ (21,581,637) $ (8,581,267)
BASIC NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE $ (0.74) $ (0.76)
DILUTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE $ (0.74) $ (0.76)
SHARES USED IN COMPUTING BASIC NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE 29,346,679 11,261,217
SHARES USED IN COMPUTING DILUTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE 29,346,679 11,261,217